Mississauga: GSK's AREXVY (respiratory syncytial virus vaccine - recombinant, AS01E adjuvanted) has been approved in Canada ...
In a report released today, Emily Field from Barclays maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target of £14.50. The company’s shares closed yesterday at ...
WASHINGTON — Pharmaceutical industry giant GSK plans to depart the biotechnology industry’s largest trade group, the ...
In May 2024, GSK announced positive headline results from the phase III clinical trials SWIFT-1 and SWIFT-2, which assessed the efficacy and safety of depemokimab versus placebo in adults and ...
Clinical study reports for the FURI, CARES and NATURE trials in refractory or resistant invasive fungal infections were delivered to GSK, ...
Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenibExpected to fund Syndax through profitability; proforma cash approaching $800 mil ...
CureVac Strengthens Leadership Team with Appointment of Seasoned industry Executive Axel Sven Malkomes as Chief financial Officer ...
The heat has been out of the life sciences market over the last 18 months, but new VC investments could fuel a comeback for ...
According to two reports released Thursday by the Nebraska Department of Revenue, the state signed fewer than 40 tax ...
Each year, up to 160,000 older adults living in the United States are hospitalized and as many as 10,000 die due to respiratory syncytial virus (RSV). RSV is a highly contagious virus that spreads ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback